COMP <GO>
CTKB vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Cytek Biosciences Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: CTKB 1
— LLY 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: LLY
LAST: $6.30 (+2.61%) • MKT CAP: $818.9M
dividend-safety
0.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTKB VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTKB | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.80% | 83.64% | -31.84 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.70% | 32.36% | -45.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.07% | 2.30% | -3.37 | LLY | /fcf-yield <GO> |
| Operating Margin | -20.00% | 40.21% | -60.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -33.00% | 31.90% | -64.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 0.50% | 45.51% | -45.01 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.76 | 9.29 | -4.53 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.7 | 66.6 | +2.10 | CTKB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $818.9M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTKB REV | LLY REV | CTKB GROSS % | LLY GROSS % | CTKB FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $201.5M | $65.18B | 51.8% | 83.0% | -$8.8M | $16.81B |
| FY 2024 | $200.5M | $45.04B | 55.4% | 81.3% | $21.9M | $8.82B |
| FY 2023 | $193.0M | $34.12B | — | 79.3% | $5.3M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTKB // BETA —
LLY // BETA 0.51